1025953-07-4

Basic information

• Product Name: N-methyl-2-methylamino-N-{1-[methyl-(1-methyl-piperidin-4-yl)-carbamoyl]-2-phenyl-ethyl}-3-naphthalen-2-yl-propionamide
• Synonyms: N-methyl-2-methylamino-N-{1-[methyl-(1-methyl-piperidin-4-yl)-carbamoyl]-2-phenyl-ethyl}-3-naphthalen-2-yl-propionamide
• CAS NO: 1025953-07-4
• Molecular Weight: 500.684
• Mol File: 1025953-07-4.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: N-methyl-2-methylamino-N-{1-[methyl-(1-methyl-piperidin-4-yl)-carbamoyl]-2-phenyl-ethyl}-3-naphthalen-2-yl-propionamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-methyl-2-methylamino-N-{1-[methyl-(1-methyl-piperidin-4-yl)-carbamoyl]-2-phenyl-ethyl}-3-naphthalen-2-yl-propionamide(1025953-07-4)
• EPA Substance Registry System: N-methyl-2-methylamino-N-{1-[methyl-(1-methyl-piperidin-4-yl)-carbamoyl]-2-phenyl-ethyl}-3-naphthalen-2-yl-propionamide(1025953-07-4)

Safety Data

• Hazardous Substances Data: 1025953-07-4(Hazardous Substances Data)

Upstream product

• 1027232-41-2 Methyl-[(R)-1-(methyl-{(R)-1-[methyl-(1-methyl-piperidin-4-yl)-carbamoyl]-2-phenyl-ethyl}-carbamoyl)-2-naphthalen-2-yl-ethyl]-carbamic acid tert-butyl ester 
• 1026432-09-6 methyl-{1-[methyl-(1-methyl-piperidin-4-yl)-carbamoyl]-2-phenyl-ethyl}-carbamic acid tert-butyl ester 
• 37553-65-4 N-tert-butoxycarbonyl-N-methyl-D-phenylalanine 
• 73579-08-5 Methyl-(1-methyl-[4]piperidyl)-amin 

Relevant articles and documents

The influence of conformational restriction in the C-terminus of growth hormone secretagogues on their potency

In order to obtain more potent growth hormone secretagogues, a comparison of ipamorelin and NN703 suggested the addition of a polar group at the C-terminus of NN703. A study was conducted using constrained amines for this purpose. Here, substituted 4-piperidinylamino- and 4-dimethylaminopiperidino-substitutents were found to give the most active compounds. A replacement of the 4-dimethylaminopiperidino-substituent with 4-hydroxypiperidino resulted in a series of compounds, which showed in vitro activity with EC50 values in the low nanomolar range, and favourable kinetic properties, such as 40% oral bioavailability. The most promising compound was also tested in a swine in vivo model, resulting in a growth hormone level with a Cmax of over 40 ng mL-1.